About ACT Biotech
ACT Biotech is a Healthcare company based in San Francisco (United States) founded in 2008, and was acquired by Eddingpharm in January 2014. Small molecule kinase inhibitors for cancer therapy are developed. ACT Biotech has raised $9.07 million across 4 funding rounds from investors including Eddingpharm and NGN Capital. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
ACT Biotech, is a biopharmaceutical company that develops oral small molecule kinase inhibitors as anti-cancer drugs. Its products include drugs with mechanisms of action in areas, such as signal transduction and anti-angiogenesis. The lead asset, Telatinib, is a VEGFR inhibitor ready for Phase III development for gastric cancer. The other two programs ACTB1003 (FGFRVEGFR2 inhibitor) and ACTB1010 (aurora kinases inhibitor) are in Phase I-ready and preclinical stages, respectively. In 2014, Chinese firm Eddingpharm acquired the global rights to Telatinib, ACTB1003 and ACTB1010 from ACT Biotech
- Headquarters San Francisco, United States
- Stage Acquired
- SectorsHealthcare
- Website actbiotech.com
- Social LinkedIn
- Acquired by Eddingpharm (Jan 2014)
- Total Equity Funding$9.07M (USD)
in 4 rounds
- Latest Funding Round$1M (USD), Series A
Jun 2010
- InvestorsEddingpharm
& 1 more
- Acquired byEddingpharm
(Jan 2014)
Funding Insights of ACT Biotech
ACT Biotech has successfully raised a total of $9.07M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $1 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.07M
- Total Rounds 4
- Last Round Series A — $1M
- First Round $6.57M
(May 2008)
- Investors Count 1
All 4 funding rounds of ACT Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2010 | $1M | Series A | – | – | – |
| Apr 2010 | $1M | Series A | – | – | – |
| Oct 2009 | $500,000 | Series A | – | – | – |
| May 2008 | $6.57M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in ACT Biotech
ACT Biotech has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Eddingpharm and NGN Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
NGN Capital is engaged in venture capital investments. | ngncapital.com | New York, United States | ||
Provider of biopharmaceutical products for critical illnesses | 2001 | eddingpharm.com | Shanghai, China |
Investor details for ACT Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ACT Biotech
4 dated milestones of ACT Biotech across 6 years, from founding to its latest funding, stage changes and deals.
- Founded ACT Biotech is founded.
- Funding First funding round of $6.6M.
- Funding Latest funding round, Series A, of $1.0M.
- Exit Acquired by Eddingpharm.
Competitors of ACT Biotech
ACT Biotech has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of ACT Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as ACT Biotech (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ACT Biotech
ACT Biotech was founded in 2008.
ACT Biotech is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
ACT Biotech is a funded company, having raised a total of $9.07M across 4 funding rounds to date. The company's 1st funding round was a Series A of $6.57M, raised on May 2008.
ACT Biotech, is a biopharmaceutical company that develops oral small molecule kinase inhibitors as anti-cancer drugs. Its products include drugs with mechanisms of action in areas, such as signal transduction and anti-angiogenesis. The lead asset, Telatinib, is a VEGFR inhibitor ready for Phase III development for gastric cancer. The other two programs ACTB1003 (FGFRVEGFR2 inhibitor) and ACTB1010 (aurora kinases inhibitor) are in Phase I-ready and preclinical stages, respectively. In 2014, Chinese firm Eddingpharm acquired the global rights to Telatinib, ACTB1003 and ACTB1010 from ACT Biotech.
ACT Biotech has 2 investors. Key investors include Eddingpharm, and NGN Capital.
Yes. ACT Biotech was acquired by Eddingpharm in January 2014.